This content is from: Premium
Biopharma’s Healthy Private Market
Viking and Citadel are among seven hedge fund firms that participated in four financings last week.
While the volume of financings of private companies has sharply slowed this quarter, the appetite for financing fledgling biopharma and life sciences companies has still not been sated.In fact, last week alone, six private biopharma companies raised close to a combined $1 billion. And at least seven firms known for
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.